Seres Therapeutics, Inc. - Common Stock (MCRB)
0.3999
-0.0621 (-13.44%)
NASDAQ · Last Trade: Apr 16th, 9:38 PM EDT
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · April 15, 2025
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · April 14, 2025
Via Benzinga · April 14, 2025
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · March 12, 2025
Via Benzinga · March 12, 2025

Via Benzinga · January 16, 2025

Via Benzinga · October 24, 2024

Via Benzinga · September 26, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024

Via Benzinga · June 7, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 8, 2024

Via Benzinga · May 8, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · March 6, 2024

Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally.
Via InvestorPlace · March 5, 2024

MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 5, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via Benzinga · March 5, 2024